DEPO


Analysts Weigh in on Two Plummeting Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX) and Depomed Inc (DEPO)

It’s a volatile day for biotech stocks Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Depomed Inc (NASDAQ:DEPO) today, with both on a sharp descent …

Company Update (NASDAQ:DEPO): Here’s Why Depomed Inc Shares Are Falling 20% Today

Depomed Inc (NASDAQ:DEPO) investors are having a rough day after the drug maker posted weak third-quarter results and lowered its guidance. DEPO reported $110.

Depomed Inc (DEPO) Announces 3Q:16 Financial Results; Shares Down 13%

Depomed Inc (NASDAQ:DEPO) reported financial results and highlighted operational achievements for the quarter ended September 30, 2016. “Although our third quarter revenues increased by …

Company Update (NASDAQ:DEPO): Depomed Inc and Starboard Announce Settlement Agreement

Depomed Inc (NASDAQ:DEPO) announced that it has entered into a settlement agreement with its second largest shareholder, Starboard Value LP (together with its affiliates, …

Stock Update (NASDAQ:DEPO): Depomed Inc Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025

Depomed Inc (NASDAQ:DEPO) announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in …

Mizuho Top Analyst Dives In On Depomed Inc (DEPO) As The Drugmaker Exploring Sale

In pre-market trading, Depomed Inc (NASDAQ:DEPO) shares rose over 15% to $24.49 following a Reuters article indicating that the drug maker may be exploring a sale, and could begin …

Company Update (NASDAQ:DEPO): Data from Depomed Inc’s Highly-Differentiated Pain and CNS-Focused Product Portfolio Presented at PAINWeek 2016

Depomed Inc (NASDAQ:DEPO) announced the presentation of clinical data from 10 trials and studies involving NUCYNTA® ER, Gralise® Lazanda® and a novel, first-in-class investigational …

Analyst Bullish Towards Depomed Inc (DEPO)

Analyst Ken Trbovich from Janney Montgomery reiterated his buy rating for Depomed Inc (NASDAQ:DEPO) with a price target of $28, marking a 43% …

Piper Jaffray Analyst Downgrades Depomed Inc (DEPO)

Piper Jaffray analyst  David Amsellem downgrades Depomed Inc (NASDAQ:DEPO) from Overweight to Neutral with a a price target of $18.00.

UBS Downgrades Depomed Inc (DEPO)

UBS analyst Ami Fadia has downgraded DepoMed Inc (NASDAQ:DEPO) from Buy to Hold. The analyst sees risk in management’s 2016 sales guidance of …